Login to Your Account

Deals And M&A NEWS

With a pair of drugs devoted to what Ionis Pharmaceuticals Inc. CEO Stanley Crooke called "systematically knocking off the remaining lipid risk factors" for patients facing CV trouble, the company closed a potential $1.6 billion deal with Novartis AG.

Startup Delinia Inc. hitched its potentially transformative immune regulatory wagon to the Celgene Corp. train, agreeing to a potential $775 million acquisition.

An adenoviral gene delivery technology developed by Genvec Inc. has drawn active synthetic biology player Intrexon Corp. to acquire the company in a stock exchange Intrexon valued at about $7 per share, or about $19.4 million.

More Deals And M&A Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: